Based on the results of the phase III Study 301, Vyxeos Liposomal was approved in Europe in 2018 for the treatment of adult patients with newly diagnosed therapy-related acute myeloid leukaemia (AML) and AML with myelodysplasia-related changes. Since then, various real-world studies have assessed the safety and efficacy of this drug in routine clinical practice. The real-world evidence that was obtained not only supports the results from the clinical trial but also addresses an important data gap in terms of the achievement of minimal residual disease (MRD) negativity. Below we summarize the real-world experience with Vyxeos Liposomal in patients with high-risk AML.